ImmunityBio, Inc. [IBRX] Securities Class Action Lawsuit Update

• Case Name: Douglas v. ImmunityBio, Inc. et al.
• Case No.: 2:26-cv-03261
• Jurisdiction: United States District Court for the Central District of California
• Filed on: March 26, 2026
• Class Period: January 19, 2026 – March 24, 2026

Introduction

ImmunityBio investors are now confronting a fast-moving securities class action after the company’s promotional claims about Anktiva collided with a sharply worded FDA warning letter and a steep one-day stock collapse. According to the complaint, filed in the Central District of California, investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 allege that the company and Executive Chairman Dr. Patrick Soon-Shiong materially overstated Anktiva’s approved uses and efficacy, particularly by promoting it as capable of treating “all cancers,” preventing cancer after radiation exposure, and functioning as a “cancer vaccine.”

The lawsuit alleges that those misstatements were revealed when the FDA Warning Letter was publicized on March 24, 2026.

The market reaction was immediate: IBRX fell $1.98, or 21%, to close at $7.42 that day, according to the complaint.

“Most IBRX shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

ImmunityBio is a biotechnology company, and the complaint centers on Anktiva, its lead biologic product. The pleading emphasizes that the drug’s approved use is narrow: BCG-unresponsive, high-risk NMIBC with CIS with or without papillary disease, not the sweeping cancer-treatment and prevention claims allegedly made during the class period.

The alleged misconduct arose from a January 19, 2026 podcast appearance by Dr. Soon-Shiong, later linked on the company’s website, where he described Anktiva as “the most important molecule that could cure cancer” and said it could “treat all cancers.” The complaint alleges those remarks contributed to inflated investor expectations regarding Anktiva’s commercial scope and scientific promise.

Promises Made vs. Reality

The core contrast in the complaint is stark. Investors allege that ImmunityBio publicly presented Anktiva as a transformational oncology platform while the FDA later concluded the company lacked data supporting those claims.

The complaint quotes the January podcast statements, including:

• Anktiva was “on the path to curing the cancer”
• It could “treat all cancers”
• It could “prevent cancer if you were exposed to radiation”
• It was the only therapy left after checkpoint inhibitor failure in lung cancer

But the FDA warning letter, reproduced extensively in the complaint, said the QUILT-3.032 study only established efficacy in combination with BCG, and even then showed a 62% complete response rate, not universal long-term remission. The FDA further stated it was not aware of data supporting claims that Anktiva alone cures cancer, works across all cancers, or has any preventative effect.

The complaint also stresses route-of-administration concerns: while the podcast and TV ad allegedly depicted subcutaneous injection, the FDA said Anktiva is approved for intravesical use only.

Timeline of Alleged Misconduct and Disclosures

The alleged fraud period is concise and tightly linked to a single promotional cycle.

On January 19, 2026, Dr. Soon-Shiong appeared on a podcast and allegedly made sweeping efficacy and indication statements about Anktiva. Investors claim these remarks materially overstated the drug’s approved uses and scientific support.

On March 24, 2026, the market learned that the FDA had issued a warning letter dated March 13, criticizing both the TV ad and podcast as false or misleading promotional communications. The letter specifically rejected claims that Anktiva could cure cancer broadly, prevent cancer, or be used for off-label injectable administration.

That same day, Bloomberg reported on the warning, and the stock fell 21%, which the complaint identifies as the corrective disclosure event.

Investor Harm and Market Reaction

The investor harm theory is classic loss causation: that IBRX traded at inflated prices until the market learned of the FDA’s criticism of the challenged promotional statements.

According to the complaint, the $1.98 per share decline erased substantial shareholder value in a single session. The complaint links that decline to the public disclosure of the FDA’s criticism that the promotional materials “grossly misrepresent the benefits of Anktiva.”

For investors, the significance goes beyond one trading day. The allegations raise familiar biotech red flags: promotional overreach, unsupported extrapolation from single-arm data, and aggressive discussion of off-label use cases before robust regulatory support.

Litigation and Procedural Posture

The action is filed in the U.S. District Court for the Central District of California, Case No. 2:26-cv-03261. The complaint asserts Section 10(b) and Rule 10b-5 and Section 20(a) control-person liability. The complaint alleges scienter based in part on Dr. Soon-Shiong’s personal participation in the podcast statements and his senior scientific and management roles. The proposed class includes all purchasers of publicly traded ImmunityBio securities during the class period who were damaged thereby.

SEC Filings & Risk Factors

The complaint’s most important regulatory overlay is not a 10-K risk factor but the FDA’s formal warning letter, which functionally operates as the central risk realization event in the pleading.

The FDA allegedly found false or misleading efficacy claims, promotion of unapproved uses, unsupported prevention claims, misleading administration-route depictions, and failure to timely submit the podcast at initial dissemination.

For biotech investors, the lesson is familiar: promotional language can become securities fraud exposure when it outruns the approved label and the actual clinical record.

Implications for Investors

This ImmunityBio securities class action is, at its core, a biotech disclosure case about the distance between a company’s scientific narrative and what regulators say the evidence actually supports.

The allegations matter because they focus on one of the most sensitive zones in biotech investing: label scope inflation. When management describes a narrow bladder-cancer therapy as potentially effective across all cancers, investors may price in a much larger revenue opportunity than the science or the FDA permits. That gap can close violently.

The lawsuit centers on whether that gap reflected mere optimism or actionable securities fraud.

How to Join the ImmunityBio (IBRX) Class Action

• Confirm you purchased IBRX shares during January 19, 2026 through March 24, 2026
• Review the complaint allegations and claimed losses
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.